Clarivate Plc Stock Price, News & Analysis

Clarivate (NYSE: CLVT) released its Companies to Watch: Rediscovering Women's Health report on November 13, 2025, spotlighting seven startups advancing therapies and research across reproductive care, chronic disease and mental health.

The report cites persistent underinvestment—women's health receives 15% of venture capital and 5% of global healthcare R&D funding—and highlights clinical-stage programs and financing momentum for named companies including Daré Bioscience, Freya Biosciences, Gesynta Pharma, Granata Bio, Hope Medicine, Oxolife and Reunion Neurosciences.

Methodology relied on Clarivate proprietary sources (Cortellis deals, clinical, regulatory and competitive intelligence) to assess proof of concept, milestones, collaborations, capital raised and intellectual property.

Clarivate (NYSE:CLVT) released the Highly Cited Researchers 2025 list on November 12, 2025, recognizing 6,868 individuals with 7,131 awards from 1,300+ institutions in 60 countries.

Key metrics: the U.S. leads with 2,670 awards (37%); Mainland China second with 1,406 awards (20%); Chinese Academy of Sciences tops institutions with 258 awards. The program added scrutiny in 2025 and excluded 432 potential awards for hyper-prolific publication; Mathematics was reintroduced.

Clarivate (NYSE: CLVT) announced on November 6, 2025 that FUJIFILM Holdings selected IPfolio, Clarivate's cloud-based IP management platform, to consolidate and manage Fujifilm's intellectual property across its healthcare, electronics, business innovation and imaging businesses.

IPfolio will provide a single workflow platform for the IP lifecycle, enable faster IP decision-making, improve measurement of IP activities, and integrate with internal and external systems to support Fujifilm's AI/DX-era IP transformation and corporate value goals.

Clarivate (NYSE:CLVT) released the Pulse of the Library 2025 report on October 30, 2025, based on 2,032 responses across 109 countries. The survey finds 67% of libraries exploring or implementing AI (up from 63% in 2024) and links higher AI literacy, formal training (28%), dedicated time/resources (23.3%) and manager encouragement (24.2%) to stronger implementation and confidence. Regional gaps are notable: Asia and Europe show larger implementation gains (37–40% in initial implementation or beyond) while the U.S. reports only 7% optimism about AI benefits. Budget pressures persist, with ~50% of U.S./North American respondents expecting collections cuts.

Clarivate (NYSE: CLVT) reported third-quarter 2025 results for the period ended September 30, 2025, showing stable revenue and improved cash returns.

Total Q3 revenue was $623.1M (up 0.1% YoY). Organic ACV grew 1.6% year-over-year and the recurring-revenue mix improved 800 basis points to 88% through nine months. Q3 net loss narrowed to $28.3M (−$0.04/share) versus −$65.6M a year earlier; adjusted EBITDA was $252.4M (down 4.5% YoY).

Through nine months Clarivate generated $468.6M operating cash flow and $276.1M free cash flow, repurchased ~34.8M shares (~$150M) including 11.7M in Q3, and repaid $100M of debt. The company raised full-year 2025 revenue guidance to $2.42B–$2.45B.

Clarivate (NYSE: CLVT) announced that Winbond selected and implemented Clarivate's cloud-based IP management platform IPfolio on October 7, 2025.

The implementation delivered concrete results: a 90% improvement in data accuracy via integration with Clarivate IP data, a 25% increase in internal operational efficiency, and an estimated 15% reduction in management time through automation, real-time reporting, email document archiving, and partner collaboration. The rollout also increased the frequency of real-time patent data updates and functions as a virtual IP administrator for Winbond.

Clarivate (NYSE: CLVT) announced it will report third-quarter 2025 financial results before the market opens on Wednesday, October 29, 2025.

The company will publish a press release and earnings supplement with financial information on its investor website and will host a conference call and webcast at 9:00 AM ET on October 29, 2025 to review results. The live webcast is open to all and can be accessed via the investor relations site or the specified Q4 events link.

U.S. participants may dial 800-715-9871 and international participants may dial +1 646-307-1963 (conference ID 7007526). A replay will be posted on the investor website two hours after the call and will remain available for one year.

Clarivate (NYSE:CLVT) has launched two new AI-powered solutions for its Innography platform: AI Classifier and SEP Analyzer. The AI Classifier achieves up to 97% first-pass accuracy in patent classification and can reduce classification time from weeks to minutes, leveraging supervised machine learning and large language models (LLMs).

The SEP Analyzer focuses on streamlining standard essential patent research by providing normalized data and clear visualizations for licensing negotiations. Both tools are designed to enhance patent portfolio management and strategic decision-making capabilities for Innography customers.

Clarivate (NYSE:CLVT) has announced its 2025 Citation Laureates, recognizing 22 researchers whose work demonstrates Nobel-class influence. The program, which has successfully identified 83 eventual Nobel Prize winners since its inception, uses Web of Science citation data to select researchers from an elite group representing less than 0.02% of over 64 million indexed publications.

This year's cohort includes researchers from eight countries, with a historic first Citation Laureate from Mainland China, Professor Tao Zhang, recognized for pioneering single-atom catalysis. The laureates' research spans critical fields including leukemia treatment, quantum computing, energy storage, and economic inequality, with ten based in the United States and others across Europe and Asia.